Recent results from the SURTAVI trial add to mounting evidence that transcatheter aortic valve replacement (TAVR) can fully match surgical aortic valve replacement for safety and efficacy in appropriately selected patients at intermediate surgical risk. In the one-minute video below, Cleveland Clinic interventional cardiologist Amar Krishnaswamy, MD, puts the SURTAVI findings in context and offers perspective on the heart team approach that’s needed to help patients make the best choice between these two good treatment options.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
For a more detailed (eight-minute) video by Dr. Krishnaswamy on TAVR’s role in intermediate-risk patients, see the video here.